3 results match your criteria: "Institut Gustave Roussy and University Paris-Sud XI[Affiliation]"
Approach to the patient with advanced differentiated thyroid cancer.
Eur J Endocrinol
January 2012
Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, 94800 Villejuif, France.
Article Synopsis
- Patients with advanced thyroid cancer may benefit from l-thyroxine treatment to lower TSH levels, alongside local interventions and radioiodine therapy.
- Those who don't respond to radioiodine have limited success with chemotherapy, showing poor efficacy.
- Kinase inhibitors have shown promising results and are recommended as a first-line treatment, ideally within clinical trials.
18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer.
Eur J Nucl Med Mol Imaging
December 2010
Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy and University Paris-Sud XI, 94805, Villejuif Cedex, France.
Purpose: Our aim was to evaluate in anaplastic thyroid carcinoma (ATC) patients the value of 18F-FDG PET/CT compared with total body computed tomography (CT) using intravenous contrast material for initial staging, prognostic assessment, therapeutic monitoring and follow-up.
Methods: Twenty consecutive ATC patients underwent PET/CT for initial staging. PET/CT was performed again during follow-up.
Molecular targeted therapies for patients with refractory thyroid cancer.
Clin Oncol (R Coll Radiol)
August 2010
Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris-Sud XI, Villejuif, France.
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
View Article and Find Full Text PDF